Chapter 1: Introduction–When Even the Act of Breathing is a Burden
Every breath they take is a difficult reminder of how different things are for people suffering from COPD, or recovering from recent post-viral lung injury, or chronic lung inflammation. Among the body’s organs, the lungs are among the most biologically complex and structurally fragile and when their architecture is disturbed, natural repair processes are slow, incomplete, and often convoluted.
In particular, UC-MSC therapy for lung disease is an area of increasing scientific interest because conventional respiratory medicine, despite its importance, primarily focuses on symptoms rather than the biological environment that sustains chronic inflammation and impairs gas exchange. On the other end of the spectrum, utilizing umbilical cord-derived mesenchymal stem cells to support lung inflammation works through a different biological paradigm: it does not create a promise of regenerating lung tissue but an evidence-based strategy of improving the microenvironment surrounding the lungs decreasing chronic inflammation, modulating immune processes, and establishing conditions whereby the lung can function better.
Now being one of the world’s leading scientists in what happens inside the chronically inflamed lung.
An insight into what goes wrong in chronic lung disease is needed to understand why UC-MSCs, COPD treatment, and stem cell post-viral lung recovery make biological sense.
Multi-Level Injury in Conditions such as COPD and post-viral lung injury
Chronic airway inflammation — The bronchi and bronchioles become chronically inflamed, leading to increased mucus production, airway wall thickening, and narrowed passages that obstruct airflow. This inflammation is perpetuated by activated neutrophils and macrophages, which persist well after the inciting microbiota have been cleared.
Alveolar injury — The alveoli, the little air sacs where oxygen crosses into the bloodstream, are gradually damaged or become thicker as a result of fibrotic alteration, thus decreasing the surface area available for gas exchange. This irreversible structural loss makes alveolar repair stem cell therapy one of the more active areas of both clinical and bench UC-MSC research.
Injury to small vessels — The pulmonary capillary network encircling the alveoli is similarly susceptible. The decrease in UC-MSCs’ oxygen exchange support, driven by a gradual increase in vascular inflammation, endothelial dysfunction, and microvascular loss, limits the availability of oxygenated blood to tissues despite partial airflow.
Dysregulated immune cells — Alveolar macrophages, the immune cells expected to clear debris and resolve inflammation, are persistently activated in chronic lung disease. Instead of healing, this chronic macrophage activation contributes to tissue injury. The modulation of macrophages in the lungs by UC-MSCs is one of the most studied mechanisms in pulmonary stem cell research.
The Role of UC-MSCs in the Respiratory Microenvironment
Although UC-MSC respiratory microenvironment support occurs through similar paracrine, anti-inflammatory, and immunomodulatory mechanisms that make these cells functional across multiple organ systems, these effects are particularly relevant in the lung environment.
Paracrine lung signaling through UC-MSC offers a rich cocktail of bioactive molecules to inflamed respiratory tissues:
Anti-inflammatory mediators – such as IL-10, TGF-β, and PGE2, which decrease the prolonged neutrophilic and macrophage-driven inflammation that maintains airway injury in COPD and post-viral damage
Angiogenic signals — secretion of VEGF and FGF, sustaining the pulmonary microvasculature to protect the small vessel network critical for effective gas exchange
Extracellular vesicles and exosomes — laden with microRNA cargo that can influence gene expression in lung epithelial and endothelial cells to promote cellular repair, modulate the oxidative stress response
Keratinocyte growth factor (KGF) — a mediator crucial to alveolar epithelial repair, promoting type II pneumocyte proliferation that is central to restoring alveolar architecture
Conclusions: Anti-inflammatory UC-MSC lung effects are directed against alveolar macrophages. UC-MSCs reprogram macrophages with a pro-inflammatory (M1) phenotype into an anti-inflammatory, pro-repair (M2) state that facilitates the transition of nasal tissues from chronic damage to active resolution.
COPD: Addressing the Inflammatory Cycle
The general approach taken in treating UC-MSCs COPD is to break the self-perpetuating inflammatory cycle characteristic of chronic obstructive pulmonary disease. In COPD, progressive losses of respiratory capacity are due to destructive changes in alveolar walls (emphysema), paired with chronic bronchitis and small airway fibrosis.
The shocking news is that stem cell COPD supportive care does not reverse the established emphysema. Current biological interventions cannot restore the structural losses of alveolar tissue. The potential for mesenchymal stem cells respiratory inflammation therapy is a reduction of the chronic inflammatory burden — amelioration of ongoing injury, reduction in exacerbation-associated inflammation and maintenance of integrity and function from preserved lung tissue.
Chronic lung inflammation stem cell support in COPD should therefore be seen as an adjunct to biological therapy — it adds another layer of management for patients who are optimized on bronchodilator therapy, pulmonary rehabilitation and pharmacological approaches but remain symptomatic.
Lungs literally undergo different shapes and kinds of remodeling after injury (or it wouldn’t do any repairing from a post-viral perspective).
For post-viral lung injury — including the possible permanent changes that may follow acute, severe respiratory viral infections, known as post-acute sequelae of SARS-CoV-2 infection (PASC) — the particular type of damage is characterized by continued evidence of an inflammatory background: alveolar thickening driven by inflammation, fibrotic alterations in lung parenchyma, impaired diffusion capacity, and chronic fatigue over time secondarily to decreased efficiency of oxygen exchange.
This integrates many aspects of this picture in parallel by stem cell post-viral lung repair with UC-MSCs. UC-MSC airway inflammation therapy specifically targets residual inflammatory activity that drives fibrotic remodeling after acute infection resolution. Circulating UC-MSCs have all the machinery to support oxygen exchange via pro-angiogenic and alveolar epithelial repair signals, which may explain slowly increasing diffusion capacity in patients with persistent post-viral respiratory impairment.
Stem cell therapy for pulmonary post-viral recovery is a topic of active clinical interest, based on early-phase observations showing potential benefit, and should be pursued in selected patients with documented diffusion impairment and residual breathlessness and exercise limitation not explained by other causes (Level 2b).
Figure 1: UC-MSCs as Supportive Care in COPD and Post-Viral Lung Injury
Honest Scope: Supportive Respiratory Care
This also justifies the UC-MSC therapy in lung disease, given the rationale of respiratory stem cell clinical support. Several important boundaries apply:
UC-MSC therapy does not give rise to diseased alveoli or address predetermined emphysema
It is in addition to bronchodilators, inhaled corticosteroids, oxygen therapy, and pulmonary rehabilitation.
What’s different about UC-MSC therapy for lung disease is that it does not restore a lung. It provides a less inflammatory milieu, an improved perfused pulmonary vascular bed and a biological cue to repair—within which the extraordinary plasticity of the respiratory system is more likely to express itself.
Get In Touch
Address
3/6, The Primary 101, Soi Lad Phrao 101, Lad Phrao Road, Khlong Chan, Bang Kapi District, Bangkok 10240 Thailand
vegastemcell@gmail.com
Tel & WhatsApp
+66 (0) 65 528 2599
Others Pathway
Facebook: vegastemcell
Instagram: vegastemcell
www.vegastemcell.com
TikTok: @vegastemcell
YouTube: @vegastemcell